Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study

Background and aims: Immunoglobulin replacement therapy (IgRT), administered intravenously (IVIg) or subcutaneously (SCIg), is the cornerstone treatment for patients with Common Variable Immunodeficiency (CVID). Although both modalities demonstrate similar efficacy, SCIg is associated with fewer sys...

Descripción completa

Detalles Bibliográficos
Autores: Moral Moral, Pedro, Garcia Bustos, Victor, Balastegui Martin, Héctor, Martínez Mercader, Sandra, Bracke, Carmen, Mateu, Lourdes, Solanich Moreno, Xavier, Antolí Gil, Arnau, Carrillo-Linares, Juan Luis, Robles Marhuenda, Ángel, Puchades, Francesc, Pelaez Ballesta, Ana, López Osle, Nuria, Torralba-Cabeza, Miguel Ángel, Bielsa Masdeu, Ana María, Gil Niño, Jorge, Tornador Gaya, Nuria, Pascual Castellanos, Guillem, Sánchez-Martínez, Rosario, Barragán-Casas, José Manuel, González-García, Andrés, Patier De La Peña, José Luís, López Wolf, Daniel, Mora Rufete, Antonia, Canovas Mora, Alba, Cabañero Navalon, Marta Dafne
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/222913
Acceso en línea:https://hdl.handle.net/2445/222913
http://hdl.handle.net/2445/222913
Access Level:acceso abierto
Palabra clave:Immunodeficiència
Adults
Immunoglobulines
Immunodeficiency
Adulthood
Immunoglobulins
id ES_a5dc79c4ecc3ba5d86f828d534f7aa82
oai_identifier_str oai:recercat.cat:2445/222913
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide studyMoral Moral, PedroGarcia Bustos, VictorBalastegui Martin, HéctorMartínez Mercader, SandraBracke, CarmenMateu, LourdesSolanich Moreno, XavierAntolí Gil, ArnauCarrillo-Linares, Juan LuisRobles Marhuenda, ÁngelPuchades, FrancescPelaez Ballesta, AnaLópez Osle, NuriaTorralba-Cabeza, Miguel ÁngelBielsa Masdeu, Ana MaríaGil Niño, JorgeTornador Gaya, NuriaPascual Castellanos, GuillemSánchez-Martínez, RosarioBarragán-Casas, José ManuelGonzález-García, AndrésPatier De La Peña, José LuísLópez Wolf, DanielMora Rufete, AntoniaCanovas Mora, AlbaCabañero Navalon, Marta DafneImmunodeficiènciaAdultsImmunoglobulinesImmunodeficiencyAdulthoodImmunoglobulinsBackground and aims: Immunoglobulin replacement therapy (IgRT), administered intravenously (IVIg) or subcutaneously (SCIg), is the cornerstone treatment for patients with Common Variable Immunodeficiency (CVID). Although both modalities demonstrate similar efficacy, SCIg is associated with fewer systemic adverse events and increased patient autonomy. Despite these advantages, its utilization remains limited in certain regions, particularly in the Mediterranean region. This study aimed to evaluate real-world patterns of IgRT use in Spanish CVID patients and provide a comprehensive analysis of the factors associated with IVIg and SCIg administration in routine clinical practice. Methods: A cross-sectional, multicenter study was conducted using data from the GTEM-SEMI-CVID Registry, encompassing 212 adult CVID patients receiving IgRT across Spain. Patients were grouped based on the administration route: IVIg and SCIg. Demographic, clinical, and immunological data, including IgRT modality, dosage, administration setting, and comorbidities, were collected. Comparative statistical analyses were performed to identify differences between both treatment groups. Results: Of the 212 patients, 58.5% received IVIg and 41.5% received SCIg. SCIg recipients were younger (47.5 vs. 54.8 years, p = 0.003) and predominantly treated at home (80.6% vs. 1.6%, p < 0.001), compared to those receiving IVIg. SCIg use was significantly higher in tertiary hospitals compared to secondary ones (44.4% vs. 17.4%, p = 0.0136). Infection rates, autoimmune comorbidities, weekly doses (7.2 g for IVIg vs. 7.7 g for SCIg, p = 0.142), and IgG trough levels were comparable across groups. Conclusion: This study provides real-world evidence on IgRT patterns in Spanish patients with CVID, revealing a marked increase in SCIg use over the past decade, although IVIg remains predominant, especially in secondary hospitals. Age significantly influenced the choice of modality, with IVIg preferred for older patients and SCIg for younger ones, while disease severity did not impact this decision. These findings underscore the need to optimize access to SCIg, particularly in secondary centers, to enhance patient autonomy and improve therapeutic outcomes.Frontiers Media2025202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion10 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/222913http://hdl.handle.net/2445/222913Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3389/fimmu.2025.1640290Frontiers in Immunology, 2025, vol. 16https://doi.org/10.3389/fimmu.2025.1640290cc-by (c) Moral Moral, P. et al., 2025http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2229132026-05-29T05:05:01Z
dc.title.none.fl_str_mv Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
title Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
spellingShingle Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
Moral Moral, Pedro
Immunodeficiència
Adults
Immunoglobulines
Immunodeficiency
Adulthood
Immunoglobulins
title_short Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
title_full Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
title_fullStr Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
title_full_unstemmed Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
title_sort Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study
dc.creator.none.fl_str_mv Moral Moral, Pedro
Garcia Bustos, Victor
Balastegui Martin, Héctor
Martínez Mercader, Sandra
Bracke, Carmen
Mateu, Lourdes
Solanich Moreno, Xavier
Antolí Gil, Arnau
Carrillo-Linares, Juan Luis
Robles Marhuenda, Ángel
Puchades, Francesc
Pelaez Ballesta, Ana
López Osle, Nuria
Torralba-Cabeza, Miguel Ángel
Bielsa Masdeu, Ana María
Gil Niño, Jorge
Tornador Gaya, Nuria
Pascual Castellanos, Guillem
Sánchez-Martínez, Rosario
Barragán-Casas, José Manuel
González-García, Andrés
Patier De La Peña, José Luís
López Wolf, Daniel
Mora Rufete, Antonia
Canovas Mora, Alba
Cabañero Navalon, Marta Dafne
author Moral Moral, Pedro
author_facet Moral Moral, Pedro
Garcia Bustos, Victor
Balastegui Martin, Héctor
Martínez Mercader, Sandra
Bracke, Carmen
Mateu, Lourdes
Solanich Moreno, Xavier
Antolí Gil, Arnau
Carrillo-Linares, Juan Luis
Robles Marhuenda, Ángel
Puchades, Francesc
Pelaez Ballesta, Ana
López Osle, Nuria
Torralba-Cabeza, Miguel Ángel
Bielsa Masdeu, Ana María
Gil Niño, Jorge
Tornador Gaya, Nuria
Pascual Castellanos, Guillem
Sánchez-Martínez, Rosario
Barragán-Casas, José Manuel
González-García, Andrés
Patier De La Peña, José Luís
López Wolf, Daniel
Mora Rufete, Antonia
Canovas Mora, Alba
Cabañero Navalon, Marta Dafne
author_role author
author2 Garcia Bustos, Victor
Balastegui Martin, Héctor
Martínez Mercader, Sandra
Bracke, Carmen
Mateu, Lourdes
Solanich Moreno, Xavier
Antolí Gil, Arnau
Carrillo-Linares, Juan Luis
Robles Marhuenda, Ángel
Puchades, Francesc
Pelaez Ballesta, Ana
López Osle, Nuria
Torralba-Cabeza, Miguel Ángel
Bielsa Masdeu, Ana María
Gil Niño, Jorge
Tornador Gaya, Nuria
Pascual Castellanos, Guillem
Sánchez-Martínez, Rosario
Barragán-Casas, José Manuel
González-García, Andrés
Patier De La Peña, José Luís
López Wolf, Daniel
Mora Rufete, Antonia
Canovas Mora, Alba
Cabañero Navalon, Marta Dafne
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Immunodeficiència
Adults
Immunoglobulines
Immunodeficiency
Adulthood
Immunoglobulins
topic Immunodeficiència
Adults
Immunoglobulines
Immunodeficiency
Adulthood
Immunoglobulins
description Background and aims: Immunoglobulin replacement therapy (IgRT), administered intravenously (IVIg) or subcutaneously (SCIg), is the cornerstone treatment for patients with Common Variable Immunodeficiency (CVID). Although both modalities demonstrate similar efficacy, SCIg is associated with fewer systemic adverse events and increased patient autonomy. Despite these advantages, its utilization remains limited in certain regions, particularly in the Mediterranean region. This study aimed to evaluate real-world patterns of IgRT use in Spanish CVID patients and provide a comprehensive analysis of the factors associated with IVIg and SCIg administration in routine clinical practice. Methods: A cross-sectional, multicenter study was conducted using data from the GTEM-SEMI-CVID Registry, encompassing 212 adult CVID patients receiving IgRT across Spain. Patients were grouped based on the administration route: IVIg and SCIg. Demographic, clinical, and immunological data, including IgRT modality, dosage, administration setting, and comorbidities, were collected. Comparative statistical analyses were performed to identify differences between both treatment groups. Results: Of the 212 patients, 58.5% received IVIg and 41.5% received SCIg. SCIg recipients were younger (47.5 vs. 54.8 years, p = 0.003) and predominantly treated at home (80.6% vs. 1.6%, p < 0.001), compared to those receiving IVIg. SCIg use was significantly higher in tertiary hospitals compared to secondary ones (44.4% vs. 17.4%, p = 0.0136). Infection rates, autoimmune comorbidities, weekly doses (7.2 g for IVIg vs. 7.7 g for SCIg, p = 0.142), and IgG trough levels were comparable across groups. Conclusion: This study provides real-world evidence on IgRT patterns in Spanish patients with CVID, revealing a marked increase in SCIg use over the past decade, although IVIg remains predominant, especially in secondary hospitals. Age significantly influenced the choice of modality, with IVIg preferred for older patients and SCIg for younger ones, while disease severity did not impact this decision. These findings underscore the need to optimize access to SCIg, particularly in secondary centers, to enhance patient autonomy and improve therapeutic outcomes.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/222913
http://hdl.handle.net/2445/222913
url https://hdl.handle.net/2445/222913
http://hdl.handle.net/2445/222913
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2025.1640290
Frontiers in Immunology, 2025, vol. 16
https://doi.org/10.3389/fimmu.2025.1640290
dc.rights.none.fl_str_mv cc-by (c) Moral Moral, P. et al., 2025
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Moral Moral, P. et al., 2025
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 10 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415650552709120
score 15.811543

Similares en LA Referencia